Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress

doi:10.4240/wjgs.v15.i2.142

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4833)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

306

WORD

HTML

2480

Figures (1-2)

450

Tables (1-2)

259

Sum=3559

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

190

Download

469

Sum=659

Publishing Process of This Article

Item

Count

Browse

145

Download

470

Sum=615

Feb 27, 2023 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastrointest Surg. Feb 27, 2023; 15(2): 142-162
Published online Feb 27, 2023. doi: 10.4240/wjgs.v15.i2.142

Open in New Tab Full Size Figure Download Figure

Figure 1 Evaluation of resectability for borderline resectable pancreatic cancer. SMV: Superior mesenteric vein; SMA: Superior mesenteric artery; AI: Artificial intelligence.

Open in New Tab Full Size Figure Download Figure

Figure 2 Multidisciplinary teams process for Borderline resectable pancreatic cancer. BRPC: Borderline resectable pancreatic cancer; NAT: neoadjuvant therapy; (+): No progression or downstaging of disease and no serious adverse effects; (-): Poor response to treatment, disease progression or occurrence of serious adverse effects; MDTs: Multidisciplinary teams.

Citation: Wu HY, Li JW, Li JZ, Zhai QL, Ye JY, Zheng SY, Fang K. Comprehensive multimodal management of borderline resectable pancreatic cancer: Current status and progress. World J Gastrointest Surg 2023; 15(2): 142-162
URL: https://www.wjgnet.com/1948-9366/full/v15/i2/142.htm
DOI: https://dx.doi.org/10.4240/wjgs.v15.i2.142